- Home
- PRLD vs BYSI Comparison
PRLD vs BYSI Comparison
Compare PRLD & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRLD
- BYSI
- Stock Information
- Founded
- PRLD 2016
- BYSI 2010
- Country
- PRLD United States
- BYSI United States
- Employees
- PRLD N/A
- BYSI N/A
- Industry
- PRLD Medicinal Chemicals and Botanical Products
- BYSI Biotechnology: Pharmaceutical Preparations
- Sector
- PRLD Health Care
- BYSI Health Care
- Exchange
- PRLD Nasdaq
- BYSI Nasdaq
- Market Cap
- PRLD 73.7M
- BYSI 72.1M
- IPO Year
- PRLD 2020
- BYSI 2017
- Fundamental
- Price
- PRLD $0.77
- BYSI $1.53
- Analyst Decision
- PRLD Strong Buy
- BYSI
- Analyst Count
- PRLD 2
- BYSI 0
- Target Price
- PRLD $4.50
- BYSI N/A
- AVG Volume (30 Days)
- PRLD 201.7K
- BYSI 14.1K
- Earning Date
- PRLD 03-10-2025
- BYSI 01-01-0001
- Dividend Yield
- PRLD N/A
- BYSI N/A
- EPS Growth
- PRLD N/A
- BYSI N/A
- EPS
- PRLD N/A
- BYSI N/A
- Revenue
- PRLD $7,000,000.00
- BYSI N/A
- Revenue This Year
- PRLD N/A
- BYSI N/A
- Revenue Next Year
- PRLD N/A
- BYSI N/A
- P/E Ratio
- PRLD N/A
- BYSI N/A
- Revenue Growth
- PRLD N/A
- BYSI N/A
- 52 Week Low
- PRLD $0.63
- BYSI $1.37
- 52 Week High
- PRLD $6.80
- BYSI $3.63
- Technical
- Relative Strength Index (RSI)
- PRLD 56.73
- BYSI 33.14
- Support Level
- PRLD $0.71
- BYSI $1.37
- Resistance Level
- PRLD $0.76
- BYSI $1.48
- Average True Range (ATR)
- PRLD 0.07
- BYSI 0.11
- MACD
- PRLD 0.02
- BYSI -0.02
- Stochastic Oscillator
- PRLD 91.42
- BYSI 19.15
Stock Price Comparison Chart: PRLD vs BYSI
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It has two reportable segments Plinabulin pipeline and the TPD platform.